Akebia Therapeutics, Inc. (AKBA) stock
AKBANasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.47−0.02 (-4.78%)
Close on Nov 13, 2026Market cap $131.40MP/E –Yield –
Akebia Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Akebia Therapeutics's profit margin for the twelve months ending Sep 30, 2026 was -22.6%. For fiscal 2025 it was -2.3%, against -43.3% the year before. The highest annual figure on record is -2.3% in fiscal 2025.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -2.3% | +41.1 |
| FY2024 | Dec 31, 2024 | -43.3% | −16.7 |
| FY2023 | Dec 31, 2023 | -26.7% | +5.5 |
| FY2022 | Dec 31, 2022 | -32.2% | +101.0 |
| FY2021 | Dec 31, 2021 | -133.3% | −2.6 |
| FY2020 | Dec 31, 2020 | -130.6% | −47.1 |
| FY2019 | Dec 31, 2019 | -83.5% | −14.4 |
| FY2018 | Dec 31, 2018 | -69.1% | −28.5 |
| FY2017 | Dec 31, 2017 | -40.7% | +8802.8 |
| FY2016 | Dec 31, 2016 | -8843.5% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -38.9% | −39.8 |
| Q2 FY2026 | Jun 30, 2026 | -18.1% | −18.5 |
| Q1 FY2026 | Mar 31, 2026 | -16.9% | −27.6 |
| Q4 FY2025 | Dec 31, 2025 | -21.2% | +27.8 |
| Q3 FY2025 | Sep 30, 2025 | 0.9% | +54.5 |
| Q2 FY2025 | Jun 30, 2025 | 0.4% | +20.1 |
| Q1 FY2025 | Mar 31, 2025 | 10.7% | +65.8 |
| Q4 FY2024 | Dec 31, 2024 | -49.0% | −50.1 |
| Q3 FY2024 | Sep 30, 2024 | -53.5% | −19.1 |
| Q2 FY2024 | Jun 30, 2024 | -19.7% | +0.2 |
| Q1 FY2024 | Mar 31, 2024 | -55.2% | +12.0 |
| Q4 FY2023 | Dec 31, 2023 | 1.1% | +12.0 |
| Q3 FY2023 | Sep 30, 2023 | -34.5% | +76.6 |
| Q2 FY2023 | Jun 30, 2023 | -19.8% | −43.1 |
| Q1 FY2023 | Mar 31, 2023 | -67.2% | +35.8 |
| Q4 FY2022 | Dec 31, 2022 | -10.9% | +110.2 |
| Q3 FY2022 | Sep 30, 2022 | -111.0% | +11.1 |
| Q2 FY2022 | Jun 30, 2022 | 23.3% | +180.2 |
| Q1 FY2022 | Mar 31, 2022 | -102.9% | +30.1 |
| Q4 FY2021 | Dec 31, 2021 | -121.1% | +34.1 |
| Q3 FY2021 | Sep 30, 2021 | -122.1% | −22.2 |
| Q2 FY2021 | Jun 30, 2021 | -156.9% | +38.0 |
| Q1 FY2021 | Mar 31, 2021 | -133.0% | −64.4 |
| Q4 FY2020 | Dec 31, 2020 | -155.3% | −19.4 |
| Q3 FY2020 | Sep 30, 2020 | -100.0% | −40.6 |
| Q2 FY2020 | Jun 30, 2020 | -195.0% | −137.3 |
| Q1 FY2020 | Mar 31, 2020 | -68.7% | +31.0 |
| Q4 FY2019 | Dec 31, 2019 | -135.8% | −35.5 |
| Q3 FY2019 | Sep 30, 2019 | -59.3% | −10.4 |
| Q2 FY2019 | Jun 30, 2019 | -57.7% | +12.1 |
| Q1 FY2019 | Mar 31, 2019 | -99.7% | −48.7 |
| Q4 FY2018 | Dec 31, 2018 | -100.3% | −117.5 |
| Q3 FY2018 | Sep 30, 2018 | -49.0% | +7.0 |
| Q2 FY2018 | Jun 30, 2018 | -69.8% | +5.6 |
| Q1 FY2018 | Mar 31, 2018 | -51.0% | +2415.6 |
| Q4 FY2017 | Dec 31, 2017 | 17.1% | – |
| Q3 FY2017 | Sep 30, 2017 | -56.0% | – |
| Q2 FY2017 | Jun 30, 2017 | -75.4% | – |
| Q4 FY2016 | Dec 31, 2016 | -2466.6% | – |
See a number that looks wrong?